NEWS

Bellicum Pharmaceuticals EHA Presentation Helps Validate Its Platform – Benzinga

BenzingaBellicum Pharmaceuticals EHA Presentation Helps Validate Its PlatformBenzingaThe firm said this could have broader applicability in controlling and optimizing the therapeutic index of other cell therapies, like CAR-T cells and eTCR therapeutics… Continue reading

Immunotherapy Combinations Have Mechanistic Rationale in Ovarian Cancer – Targeted Oncology

Targeted Oncology

Immunotherapy Combinations Have Mechanistic Rationale in Ovarian Cancer Targeted Oncology Differential PI3Kδ signaling in CD4+ T cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Canc Res. 2017;77(8):1892-1904. doi: 10.1158/0008-5472.CAN-16-1839. Higuchi T, Flies DB, Marion NA, et al. CTLA-4 …